Comparison between Eris Lifesciences IPO and GTPL Hathway IPO.
Eris Lifesciences IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while GTPL Hathway IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Eris Lifesciences IPO is up to ₹1,740.49 Cr whereas the issue size of the GTPL Hathway IPO is up to ₹484.80 Cr. The final issue price of Eris Lifesciences IPO is ₹603.00 per share and of GTPL Hathway IPO is ₹170.00 per share.
| Eris Lifesciences IPO | GTPL Hathway IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹10 per share |
| Issue Price (Lower) | ₹600.00 per share | ₹167.00 per share |
| Issue Price (Upper) | ₹603.00 per share | ₹170.00 per share |
| Issue Price (Final) | ₹603.00 per share | ₹170.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹60.00 per share | |
| Market Lot Size | 24 shares | 88 shares |
| Fresh Issue Size | 0 shares | 1,41,17,650 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹240.00 Cr |
| OFS Issue Size | 2,88,75,000 shares | 1,44,00,000 shares |
| OFS Issue Size (Amount) | up to ₹1,740.49 Cr | up to ₹244.80 Cr |
| Issue Size Total | 2,88,75,000 shares | 2,85,17,650 shares |
| Issue Size Total (Amount) | up to ₹1,740.49 Cr | up to ₹484.80 Cr |
Eris Lifesciences IPO opens on Jun 16, 2017, while GTPL Hathway IPO opens on Jun 21, 2017. The closing date of Eris Lifesciences IPO and GTPL Hathway IPO is Jun 20, 2017, and Jun 23, 2017, respectively.
| Eris Lifesciences IPO | GTPL Hathway IPO | |
|---|---|---|
| Anchor Bid Date | Jun 15, 2017 | Jun 20, 2017 |
| Issue Open | Jun 16, 2017 | Jun 21, 2017 |
| Issue Close | Jun 20, 2017 | Jun 23, 2017 |
| Basis Of Allotment (Tentative) | Jun 23, 2017 | Jun 29, 2017 |
| Initiation of Refunds (Tentative) | Jun 27, 2017 | Jun 30, 2017 |
| Credit of Share (Tentative) | Jun 28, 2017 | Jul 03, 2017 |
| Listing date (Tentative) | Jun 29, 2017 | Jul 04, 2017 |
| Anchor Lockin End date 1 | Jul 23, 2017 | Jul 29, 2017 |
| Anchor Lockin End date 2 | Sep 21, 2017 | Sep 27, 2017 |
Eris Lifesciences IPO P/E ratio is , as compared to GTPL Hathway IPO P/E ratio of .
| Eris Lifesciences IPO | GTPL Hathway IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | ||||||
| Promoter Shareholding (Post-Issue) | ||||||
| P/E Ratio | ||||||
| Market Cap | ₹8291.25 Cr. | ₹1911.87 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW |
In the Eris Lifesciences IPO Retail Individual Investors (RII) are offered 28,72,500 shares while in GTPL Hathway IPO retail investors are offered 28,72,500 shares. Qualified Institutional Buyers (QIB) are offered 86,17,500 shares in Eris Lifesciences IPO and 57,03,530 shares in GTPL Hathway IPO.
| Eris Lifesciences IPO | GTPL Hathway IPO | |
|---|---|---|
| Anchor Investor Reservation | 1,29,26,250 shares | 85,55,294 shares |
| Market Maker Reservation | ||
| QIB | 86,17,500 shares | 57,03,530 shares |
| NII | 43,08,750 shares | 42,77,648 shares |
| RII | 28,72,500 shares | 99,81,178 shares |
| Employee | 1,50,000 shares | |
| Others | ||
| Total | 2,88,75,000 shares | 2,85,17,650 shares |
Eris Lifesciences IPO subscribed 3.29x in total, whereas GTPL Hathway IPO subscribed 1.53x.
| Eris Lifesciences IPO | GTPL Hathway IPO | |
|---|---|---|
| QIB (times) | 4.68x | 1.48x |
| NII (times) | 0.45x | 2.85x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 3.51x | 0.99x |
| Employee (times) | 0.86x | |
| Other (times) | ||
| Total (times) | 3.29x | 1.53x |
